Sartorius at 5-month highs after FY guidance hike, Q3 beat

Sartorius AG

16/10/2025 08:19

** Shares in Sartorius SATG.DE rise 9% to their highest price in 5 months after the German lab equipment maker hiked FY guidance following slightly better-than expected Q3 earnings

** Sartorius now sees 7% growth in FY sales revenue (vs. 6% previously), with underlying EBITDA margin slightly above 29.5% percent at group level (vs. 29%-30% previously)

** JPM sees Q3 results slightly ahead of consensus, upgraded Bioprocess Solutions unit guidance, and improving book-to-bill ratios supporting shares

** The group reports Q3 EBITDA margin of 29.3% on EBITDA of 221 million euros  ($257.49 million), both beating consensus by 10bps and 4% respectively, according to J.P. Morgan

** Shares in the company's French unit, Sartorius Stedim Biotech STDM.PA, also rise 11.4% following its earnings

** Both names are best performers on Europe's STOXX 600 index .STOXX

($1 = 0.8583 euros)

 (Reporting by Cian Muenster)

 ((Cian.muenster@thomsonreuters.com))